METHODS: This was a prospective non-randomized clinical study. A total of 24 patients(24 eyes)with NVG were enrolled. After using intraocular pressure(IOP)-lowering drugs, the elevated IOP in 7 eyes was controlled within normal limits and 17 eyes within high levels. All patients were treated with intravitreal injection of Lucentis 0.50mg/0.05mL. Complex trabeculectomy were performed within 7d after injection. All patients were treated with panretinal photocoagulation after complex trabeculectomy. The regression of iris neovascularization, changes in IOP, best corrected visual acuity, intraoperative and postoperative complications and filtering bleb were analyzed after combined treatment. Patients were followed-up for 6-18mo.

RESULTS: Iris neovascularization completely regressed within 1wk in 24 eyes after intravitreal injection of Lucentis. The average IOP was 41.38±3.16mmHg before combined treatment,and 12.69±1.52mmHg in 6mo after combined treatment. The differences had statistically significant before and after combined treatment(F=25.592, P<0.05). Before combined treatment, the best-corrected visual acuity was >0.1 in 3 eyes, 0.01-0.1 in 10 eyes, non light perception(NLP)- finger counting(FC)in 11 eyes. After combined treatment, the best-corrected visual acuity was >0.1 in 5 eyes, 0.01-0.1 in 16 eyes, NLP～FC in 3 eyes, which showed statistically significant difference with the visual acuity before combined treatment(Z=-2.201, P<0.05).

CONCLUSION: Combined treatment could effectively control the IOP and preserve the visual function in patients with neovascular glaucoma.